This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Subscribe To Our Newsletter & Stay Updated
